High baseline FGF21 levels are associated with poor glucose-lowering efficacy of exenatide in patients with type 2 diabetes.
Kun YangHaining WangRui WeiWenhua XiaoQing TianChen WangJin YangTianpei HongPublished in: Acta diabetologica (2021)
ChiCTR-IPR-15006558, date registered May 27, 2015.